Magazine Article | May 1, 2023

Fortress Biotech's Network Flex Business Model

Source: Life Science Leader

By Ben Comer, Chief Editor, Life Science Leader

When the very first clinical data are peer-reviewed and published from a first-in-human trial of a new experimental drug candidate, it’s probably too late for Lindsay Rosenwald, chairman, president, and CEO of Fortress Biotech, to make an offer. “If a banker is shopping an opportunity, where is my competitive advantage? If it’s a really good drug, somebody’s going to pay up for it, and we try to avoid bidding wars.”

For more than 30 years, Rosenwald, an MD, financial manager, and biopharma company founder and investor, has been hunting for novel drug candidates to invest in, or to purchase directly and build companies around. During that time, Rosenwald meticulously cultivated a network of advisers, academics, and scientific experts, which he relies on to help identify promising clinical-stage drug candidates in areas of unmet need, before others find out about them.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader